8-KItem 5.02 · Officer/Director ChangeItem 9.01 · Financial Statements
DEXCOM INC (DXCM)

DexCom files 8-K (Item 9.01): Exhibit 10.1 — Letter Agreement dated Feb 27, 2026 between DexCom, Inc.

Filed with the SEC on · Summarized by InvestorsBot

DexCom files 8-K (Item 9.01): Exhibit 10.1 — Letter Agreement dated Feb 27, 2026 between DexCom, Inc. and Kevin Sayer; noted as a management/compensatory contract. 📝 $DXCM #8K #Compensation

Filing includes Inline XBRL cover page (Exhibit 104). 8-K signed by CFO Jereme M. Sylvain on March 2, 2026. 📄 $DXCM #CorporateGovernance #SECfiling

Exhibit 10.1 is now on file — investors should review the letter agreement for details on terms and potential executive compensation implications. 🔍 $DXCM #Investing #InsiderComp

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from DEXCOM INC

Dexcom Executive Chair Kevin Sayer sells $2.0M in stock

Form 4 · Insider Trade · July 21, 2026

Kevin R.

8-K · March 2, 2026

Dexcom filed Form 8‑K on Feb 26, 2026: Item 9.01 lists Exhibit 99.1 (press release dated Feb 26, 2026) and…

8-K · February 26, 2026

Dexcom ($DXCM) announced on Feb 26, 2026 the appointment of Mr.

8-K · February 26, 2026

Dexcom Board expands to 12; appointed Albert F.

8-K · February 26, 2026

Dexcom filed an 8‑K (Item 9.01) on Feb 12, 2026 — exhibits: Press Release (Ex.

8-K · February 12, 2026